Influence of MHCIITA rs3087456 and rs4774 polymorphisms in the susceptibility to cardiovascular disease of patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 1, 2012, Pages 51-57

  García Bermúdez, Mercedes ^a   González Juanatey, Carlos ^b   Lopez Mejias, Raquel ^c   Rodriguez Rodriguez, Luis ^a,d   Pérez Esteban, Silvia ^e   Castañeda, Santos ^e   Urcelay, Elena ^d   Miranda Filloy, José A ^b   Gómez Vaquero, Carmen ^f   Fernández Gutierrez, Benjamín ^d   Balsa, Alejandro ^g   González Alvaro, Isidoro ^e   Blanco, Ricardo ^c   Llorca, Javier ^h   Martín, Javier ^a   González Gay, Miguel A ^c  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular disease; Genetics; MHCIITA rs3087456 ( 168A>G); Rheumatoid arthritis; rs4774 (+1614G>C)

Indexed keywords

EPITOPE;

ADULT; AGED; ALLELE; AMINO ACID SEQUENCE; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE SEVERITY; DNA POLYMORPHISM; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MHC CLASS II TRANSACTIVATOR GENE; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANS-ACTIVATORS;

EID: 84863750663     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. DEL RINCÓN I, ESCALANTE A: Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 278-86.
2. GAZI IF, BOUMPAS DT, MIKHAILIDIS DP, GANOTAKIS ES: Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007; 25: 102-11.
3. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
4. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
5. SATTAR N, MCCAREY DW, CAPELL H, MCINNES IB Explaining how " high-grade"systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
6. DESSEIN PH, JOFFE BI, VELLER MG et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435-42.
7. SATTAR N, MCINNES IB Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-92.
8. TURESSON C, JARENROS A, JACOBSSON L Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63: 952-5.
9. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MARTIN J, LLORCA J Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008; 38: 67-70.
10. GONZALEZ-JUANATEY C, LLORCA J, TESTA A, REVUELTA J, GARCIA-PORRUA C, GONZALEZ-GAY MA Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407-13.
11. CORNELIS F, FAURE S, MARTINEZ M et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 1998; 95: 10746-50.
12. MACKAY K, EYRE S, MYERSCOUGH A et al. Whole genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum 2002; 46: 632-9.
13. JAWAHEER D, SELDIN MF, AMOS CI et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 2003; 48: 906-16.
14. JOHN S, SHEPHARD N, LIU G et al. Wholegenome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites. Am J Hum Genet 2004; 75: 54-64.
15. GREGERSEN PK, SILVER J, WINCHESTER RJ The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
16. REITH W, LEIBUNDGUT-LANDMANN S, WALDBURGER JM Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 2005; 5: 793-806.
17. LEIBUNDGUT-LANDMANN S, WALDBURGER JM, KRAWCZYK M et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 2004; 34: 1513-25.
18. TING JP, TROWSDALE J Genetic control of MHC class II expression. Cell 2002; 109: 21-33.
19. MUHLETHALER-MOTTET A, OTTEN LA, STEIMLE V, MACH B Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16: 2851-60.
20. EYRE S, BARTON A, SHEPHARD N et al. Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs. Arthritis Rheum 2004; 50: 729-35.
21. SWANBERG M, LIDMAN O, PADYUKOV L et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37: 486-94.
22. IIKUNI N, IKARI K, MOMOHARA S et al. MHC2TA is associated with rheumatoid arthritis in Japanese patients. Ann Rheum Dis 2007; 66: 274-5.
23. EYRE S, BOWES J, SPRECKLEY K et al. Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort. Arthritis Rheum 2006; 54: 3417-22.
24. HARRISON P, POINTON JJ, FARRAR C, HARIN A, WORDSWORTH BP MHC2TA promoter polymorphism (-168*G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 409-11.
25. AKKAD DA, JAGIELLO P, SZYLD P et al. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet 2006; 33: 59-61.
26. YAZDANI-BIUKI B, BRICKMANN K, WOHLFAHRT K et al. The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients Arthritis Res Ther 2006; 8: R97.
27. OROZCO G, ROBLEDO G, LINGA REDDY MVP et al. Study of the role of a functional polymorphism of MHC2TA in rheumatoid arthritis in three ethnically different populations. Rheumatology (Oxford) 2006; 45: 1442-4.
28. DIEGUEZ-GONZÁLEZ R, AKAR S, CALAZA M et al. Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, eotaxin-3, and MHC2TA. J Rheumatol 2009; 36: 1590-5.
29. BRONSON PG, CRISWELL LA, BARCELLOS LF The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a metaanalysis of 6861 patients and 9270 controls reveals no evidence for association. Ann Rheum Dis 2008; 67: 933-6.
30. MARTÍNEZ A, SÁNCHEZ-LÓPEZ M, VARADÉ J et al. Role of MHC2TA gene in autoimmune diseases. Ann Rheum Dis 2007; 66: 325-9.
31. MARTÍNEZ A, PERDIGONES N, CÉNIT MC et al. Chromosomal region 16p13: further evidence of increased predisposition to immune diseases. Ann Rheum Dis 2010; 69: 309-11.
32. O'DOHERTY C, HAWKINS S, ROONEY M, VANDENBROECK K The MHC2TA -168A/ G and +1614G/C polymorphisms and risk for multiple sclerosis or chronic inflammatory arthropathies. Tissue Antigens 2007; 70: 247-51.
33. LINDHOLM E, MELANDER O, ALMGREN P et al. Polymorphism in the MHC2TA Gene is Associated with Features of the Metabolic Syndrome and Cardiovascular Mortality. PLoS ONE 2006; 1: e64. doi:10.1371/journal. pone.0000064.
34. LEE JMS, CHOUDHURY RP: Rheumatoid arthritis RA lowering cardiovascular risk with statins. Nat Rev Rheumatol 2010; 6: 123-4.
35. KWAK B, MULHAUPT F, MYIT S, MACH F Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-402.
36. CHARLES-SCHOEMAN C, KHANNA D, FURST DE et al. Effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007; 34: 1459-64.
37. ARNETT FC, EDWORTHY SM, BLOCH DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
38. GONZALEZ-JUANATEY C, LLORCA J, MARTIN J, GONZALEZ-GAY MA Carotid intimamedia thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009; 38: 366-71.
39. GONZALEZ-JUANATEY C, TESTA A, GARCIACASTELO A et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
40. GONZALEZ-JUANATEY C, LLORCA J, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150-3.
41. NG PC, HENIKOFF S Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 863-74.
42. GONZALEZ-GAY MA, GARCIA-PORRUA C, HAJEER AH Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002; 31: 355-60.
43. SKOL AD, SCOTT LJ, ABECASIS GR, BOEHNKE M Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006; 38: 209-13.
44. CARMONA L, VILLAVERDE V, HERNÁNDEZGARCÍA C et al. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 2002; 41: 88-95.
45. LÉVY L, FAUTREL B, BARNETCHE T, SCHAEVERBEKE T Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature. Clin Exp Rheumatol 2008; 26: 673-9.
46. RODRIGUEZ-RODRÍGUEZ L, GONZALEZJUANATEY C, PALOMINO-MORALES R et al. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011, 216: 125-30.
47. PALOMINO-MORALES R, GONZALEZJUANATEY C, VAZQUEZ-RODRIGUEZ TR et al. Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 695-701.
48. PALOMINO-MORALES R, GONZALEZJUANATEY C, VAZQUEZ-RODRIGUEZ TR et al. Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from Northwestern Spain. Clin Exp Rheumatol 2010; 28: 68-72.
49. RAMANUJAM R, ZHAO Y, PIRSKANEN R, HAMMARSTRÖM L Lack of association of the CIITA -168A*G promoter SNP with myasthenia gravis and its role in autoimmunity. BMC Medical Genetics 2010; 11: 147.
50. DEMA B, MARTINEZ A, FERNANDEZ-ARQUERO M et al. Autoimmune disease association signals in CIITA and KIAA0350 are not involved in celiac disease susceptibility. Tissue Antigens 2009; 73: 326-9.
51. SÁNCHEZ E, J. SABIO JM, JIMENEZ-ALONSO J et al. Study of two polymorphisms of the MHC2TA gene with systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47: 102-3.
52. LINGA-REDDY MV, GUNNARSSON I, SVENUNGSSON E et al. A polymorphic variant in the MHC2TA gene is not associated with systemic lupus erythematosus. Tissue Antigens 2007; 70: 412-4.